Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifampicin · 1 trial · 1 indication
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
The specified pharmacokinetic parameter will be summarised using descriptive statistics
| Arm | Type | Description |
|---|---|---|
| RV521 plus Itraconazole | EXPERIMENTAL | RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D7 plus Itraconazole 100 mg capsules for oral administration, a 200 mg dose administered once daily on D4 - D10, inclusive |
| RV521 plus Verapamil | EXPERIMENTAL | RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D11 plus Verapamil, 80 mg tablets for oral administration, an 80 mg dose administered TDS daily on D4 - D14, inclusive |
| RV521 plus Rifampicin | EXPERIMENTAL | RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D10 plus Rifadin, Rifampicin, 300 mg capsules for oral administration, a 600 mg dose administered once daily on D4 - D10, inclusive |
| RV521 plus Midazolam | EXPERIMENTAL | RV521 drug substance in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15 |
| Placebo plus Midazolam | PLACEBO_COMPARATOR | Placebo for RV521 in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15 |
| Name | Type | Description |
|---|---|---|
| Itraconazole | DRUG | Itraconazole capsules |
| Verapamil | DRUG | Verapamil tablets |
| Rifampicin | DRUG | Rifampicin capsules |
| Midazolam | DRUG | Midazolam oromucosal solution |
| Placebo for RV521 | DRUG | Placebo for RV521 capsules |
| RV521 | DRUG | RV521 capsules |
Inclusion Criteria: * Age 18 to 45 years, inclusive * Willing to comply with protocol defined contraception requirements * In good health with no history of major medical conditions * A body mass index (BMI) of 18 - 25 kg/m2 Exclusion Criteria: * Evidence of any clinically significant or currentl...
Rifampicin is a small molecule being investigated for use in Respiratory Syncytial Virus Infections. It is currently in Phase 1 clinical development. The drug is being studied in healthy adult participants to assess drug-drug interactions, as part of a completed trial in the United Kingdom.
Rifampicin does not have a specified molecular target or target class in the available data. Therefore, its mechanism of action is not described here. The drug is being studied for its potential effects in Respiratory Syncytial Virus Infections, though the specific biological pathway it acts on has not been disclosed.
Rifampicin is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical research on this drug for Respiratory Syncytial Virus Infections, with the drug currently in Phase 1 development.
Rifampicin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for Respiratory Syncytial Virus Infections, with one completed Phase 1 trial involving 82 participants.
Rifampicin has one completed clinical trial, identified as NCT03782662, titled "A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants." This Phase 1 trial enrolled 82 healthy adult participants in the United Kingdom and was placebo-controlled, randomized, and double-blind.
Rifampicin is not the same as Sisunatovir. The clinical trial NCT03782662, which studies drug-drug interactions, involves both drugs, but Rifampicin is a separate investigational drug. The trial is designed to assess how these drugs interact when used together in healthy participants.